Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 9/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135594 | 0.86 | GPR119 (0.47) | MEN1KMT2ALTA4H | |
| SCHEMBL10135800 | 0.84 | PRMT3 (0.47) | PRMT3SIGMAR1 | |
| SCHEMBL10135662 | 0.84 | TBK1 (0.48) | MEN1KMT2ALTA4H | |
| SCHEMBL10135807 | 0.83 | PRMT3 (0.47) | PRMT3SIGMAR1 | |
| SCHEMBL10135592 | 0.82 | GPR119 (0.50) | MEN1KMT2ALTA4H | |
| SCHEMBL567446 | 0.81 | PRMT3 (0.53) | PRMT3ROCK2MEN1KMT2A | |
| SCHEMBL1306785 | 0.80 | SIGMAR1 (0.61) | SIGMAR1P2RX7 | |
| SCHEMBL10135799 | 0.80 | PRMT3 (0.49) | PRMT3P2RX7MEN1KMT2ALTA4H | |
| SCHEMBL10135596 | 0.78 | MCHR1 (0.50) | SIGMAR1LTA4H | |
| SCHEMBL1222005 | 0.75 | SIGMAR1 (0.76) | SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | PRMT3 237/4885SIGMAR1 12/4885P2RX7 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.